Since infants with a genetic diagnosis of SMA, with one functional copy of the SMN1 gene and two or three copies of the SMN2 gene, are expected to develop severe or fatal symptoms in the first years of life, an internal control group was considered unnecessary and ethically unjustifiable. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.